Study of TEV-50717 for the Treatment of Tourette Syndrome in Children and Adolescents

- Tourette Syndrome
- Completed

Study Title: Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Teva Identifier: TV50717-CNS-30046 | 2016-000622-19

ClinicalTrials.gov Identifier: NCT03452943

Study Status: Completed

Trial Condition(s): Tourette Syndrome

Interventions: Drug: TEV-50717 | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Child

Age Range: 6 Years to 16 Years

Trial Duration: February 5, 2018 - November 12, 2019

Phase: Phase 2/3

Additional info

Synopsis

Study Type

Interventional